Logo image of BPMC

BLUEPRINT MEDICINES CORP (BPMC) Stock Price, Quote, News and Overview

NASDAQ:BPMC - Nasdaq - US09627Y1091 - Common Stock - Currency: USD

128.35  +0.15 (+0.12%)

After market: 128.35 0 (0%)

BPMC Quote, Performance and Key Statistics

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (7/3/2025, 7:05:41 PM)

After market: 128.35 0 (0%)

128.35

+0.15 (+0.12%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High128.52
52 Week Low73.04
Market Cap8.29B
Shares64.58M
Float63.82M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE123.55
Earnings (Next)07-30 2025-07-30/bmo
IPO04-30 2015-04-30


BPMC short term performance overview.The bars show the price performance of BPMC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

BPMC long term performance overview.The bars show the price performance of BPMC in the last 1, 2 and 3 years. 1 year 2 years 3 years 50 100 150

The current stock price of BPMC is 128.35 USD. In the past month the price increased by 0.2%. In the past year, price increased by 14.91%.

BLUEPRINT MEDICINES CORP / BPMC Daily stock chart

BPMC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.43 334.34B
AMGN AMGEN INC 14.37 160.37B
GILD GILEAD SCIENCES INC 14.44 139.01B
VRTX VERTEX PHARMACEUTICALS INC N/A 118.03B
REGN REGENERON PHARMACEUTICALS 12.35 59.10B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 43.28B
ARGX ARGENX SE - ADR 94.52 33.18B
ONC BEONE MEDICINES LTD-ADR 6.27 26.57B
BNTX BIONTECH SE-ADR N/A 26.44B
NTRA NATERA INC N/A 22.09B
BIIB BIOGEN INC 8.4 19.47B
SMMT SUMMIT THERAPEUTICS INC N/A 18.23B

About BPMC

Company Profile

BPMC logo image Blueprint Medicines Corp. is a precision therapy company, which engages in the provision of medicines for people with cancer and blood disorders. The company is headquartered in Cambridge, Massachusetts and currently employs 649 full-time employees. The company went IPO on 2015-04-30. The firm invents life-changing medicines in two core, strategic areas of allergy/inflammation and oncology/hematology. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and PDGFRA Exon 18 mutant GIST in the United States and Europe. The company has a pipeline of research and development programs that range from early science to advanced clinical trials in mast cell-mediated diseases, including systemic mastocytosis (SM) and chronic urticaria, breast cancer, and other solid tumors vulnerable to CDK2 inhibition. Its pipeline includes Elenestinib (BLU-263), BLU-808, and BLU-956. The company is developing Elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders. The company is advancing BLU-808, a potent and selective wild-type KIT inhibitor, for mast cell diseases.

Company Info

BLUEPRINT MEDICINES CORP

45 Sidney Street

Cambridge MASSACHUSETTS 02139 US

CEO: Jeffrey W. Albers

Employees: 649

BPMC Company Website

BPMC Investor Relations

Phone: 16173747580

BLUEPRINT MEDICINES CORP / BPMC FAQ

What is the stock price of BLUEPRINT MEDICINES CORP today?

The current stock price of BPMC is 128.35 USD. The price increased by 0.12% in the last trading session.


What is the ticker symbol for BLUEPRINT MEDICINES CORP stock?

The exchange symbol of BLUEPRINT MEDICINES CORP is BPMC and it is listed on the Nasdaq exchange.


On which exchange is BPMC stock listed?

BPMC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for BLUEPRINT MEDICINES CORP stock?

25 analysts have analysed BPMC and the average price target is 132.94 USD. This implies a price increase of 3.58% is expected in the next year compared to the current price of 128.35. Check the BLUEPRINT MEDICINES CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is BLUEPRINT MEDICINES CORP worth?

BLUEPRINT MEDICINES CORP (BPMC) has a market capitalization of 8.29B USD. This makes BPMC a Mid Cap stock.


How many employees does BLUEPRINT MEDICINES CORP have?

BLUEPRINT MEDICINES CORP (BPMC) currently has 649 employees.


What are the support and resistance levels for BLUEPRINT MEDICINES CORP (BPMC) stock?

BLUEPRINT MEDICINES CORP (BPMC) has a support level at 128.24 and a resistance level at 128.36. Check the full technical report for a detailed analysis of BPMC support and resistance levels.


Is BLUEPRINT MEDICINES CORP (BPMC) expected to grow?

The Revenue of BLUEPRINT MEDICINES CORP (BPMC) is expected to grow by 41.72% in the next year. Check the estimates tab for more information on the BPMC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BLUEPRINT MEDICINES CORP (BPMC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BLUEPRINT MEDICINES CORP (BPMC) stock pay dividends?

BPMC does not pay a dividend.


When does BLUEPRINT MEDICINES CORP (BPMC) report earnings?

BLUEPRINT MEDICINES CORP (BPMC) will report earnings on 2025-07-30, before the market open.


What is the Price/Earnings (PE) ratio of BLUEPRINT MEDICINES CORP (BPMC)?

BLUEPRINT MEDICINES CORP (BPMC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.22).


What is the Short Interest ratio of BLUEPRINT MEDICINES CORP (BPMC) stock?

The outstanding short interest for BLUEPRINT MEDICINES CORP (BPMC) is 4.9% of its float. Check the ownership tab for more information on the BPMC short interest.


BPMC Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to BPMC. When comparing the yearly performance of all stocks, BPMC is one of the better performing stocks in the market, outperforming 85.85% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

BPMC Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BPMC. BPMC may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BPMC Financial Highlights

Over the last trailing twelve months BPMC reported a non-GAAP Earnings per Share(EPS) of -3.22. The EPS increased by 57.24% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -13.03%
ROE -45.52%
Debt/Equity 1.01
Chartmill High Growth Momentum
EPS Q2Q%43.94%
Sales Q2Q%55.45%
EPS 1Y (TTM)57.24%
Revenue 1Y (TTM)99.14%

BPMC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 68% to BPMC. The Buy consensus is the average rating of analysts ratings from 25 analysts.

For the next year, analysts expect an EPS growth of 76.13% and a revenue growth 41.72% for BPMC


Ownership
Inst Owners109.31%
Ins Owners0.84%
Short Float %4.9%
Short Ratio0.94
Analysts
Analysts68
Price Target132.94 (3.58%)
EPS Next Y76.13%
Revenue Next Year41.72%